Microba Life Sciences (ASX:MAP) acquires UK's Invivo Clinical for global growth

Microba Life Sciences acquired Invivo Clinical, a microbiome testing company in the UK.

The move aligns with Microba's international testing services growth strategy, focusing on the key UK healthcare market.

The acquisition, which secured 100% of Invivo's issued share capital, grants Microba a dominant position, expanded customer base, and broader geographical reach in the UK healthcare landscape.